PMID- 27529553
OWN - NLM
STAT- MEDLINE
DCOM- 20170802
LR  - 20231105
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 8
DP  - 2016
TI  - Systematic Review: Adverse Events of Fecal Microbiota Transplantation.
PG  - e0161174
LID - 10.1371/journal.pone.0161174 [doi]
LID - e0161174
AB  - BACKGROUND: Fecal microbiota transplantation (FMT) is a microbiota-based therapy 
      that shows therapeutic potential in recurrent or refractory Clostridium difficile 
      infections and other intestinal or extra-intestinal disorders. Nonetheless, 
      adverse events (AEs) remain a major challenge in the application of FMT. AIM: To 
      review the AEs of FMT and to address the concerns of safety during the procedure. 
      METHODS: Publications were retrieved in the databases of Medline, Embase and 
      Cochrane Library. AEs were classified according to their causality with FMT or 
      their severity. RESULTS: A total of 7562 original articles about FMT were 
      identified in this study, 50 of them fulfilled the inclusion criteria. Totally 78 
      kinds of AEs were revealed enrolled in these 50 selected publications. The total 
      incidence rate of AEs was 28.5%. Among the 42 publications, 5 kinds were 
      definitely and 38 kinds were probably related to FMT. The commonest 
      FMT-attributable AE was abdominal discomfort, which was reported in 19 
      publications. For upper gastrointestinal routes of FMT, 43.6% (89/204) patients 
      were compromised by FMT-attributable AE, while the incidence dropped to 17.7% 
      (76/430) for lower gastrointestinal routes. In contrast, the incidences of 
      serious adverse events (SAEs) were 2.0% (4/196) and 6.1% (40/659) for upper and 
      lower gastrointestinal routes, respectively. A total of 44 kinds of SAEs occurred 
      in 9.2% patients, including death (3.5%, 38/1089), infection (2.5%, 27/1089), 
      relapse of inflammatory bowel diseases (0.6%, 7/1089) and Clostridium difficile 
      infection (0.9%, 10/1089). CONCLUSION: Consequently, both AEs and SAEs are not 
      rare and should be carefully monitored throughout FMT. However, high quality 
      randomized controlled trials are still needed for the more definite incidence of 
      AEs of FMT.
FAU - Wang, Sinan
AU  - Wang S
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
FAU - Xu, Mengque
AU  - Xu M
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
FAU - Wang, Weiqiang
AU  - Wang W
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
FAU - Cao, Xiaocang
AU  - Cao X
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
FAU - Piao, Meiyu
AU  - Piao M
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
FAU - Khan, Samiullah
AU  - Khan S
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
FAU - Yan, Fang
AU  - Yan F
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
AD  - Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, 
      Vanderbilt University Medical Center, Nashville, TN 37232, United States of 
      America.
FAU - Cao, Hailong
AU  - Cao H
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
AD  - Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, 
      Vanderbilt University Medical Center, Nashville, TN 37232, United States of 
      America.
FAU - Wang, Bangmao
AU  - Wang B
AD  - Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical 
      University, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160816
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Fecal Microbiota Transplantation/*adverse effects
MH  - Humans
MH  - Safety
PMC - PMC4986962
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/08/17 06:00
MHDA- 2017/08/03 06:00
PMCR- 2016/08/16
CRDT- 2016/08/17 06:00
PHST- 2016/02/27 00:00 [received]
PHST- 2016/08/01 00:00 [accepted]
PHST- 2016/08/17 06:00 [entrez]
PHST- 2016/08/17 06:00 [pubmed]
PHST- 2017/08/03 06:00 [medline]
PHST- 2016/08/16 00:00 [pmc-release]
AID - PONE-D-16-08421 [pii]
AID - 10.1371/journal.pone.0161174 [doi]
PST - epublish
SO  - PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. 
      eCollection 2016.